Have any questions? 706-721-6582 or cts@augusta.edu
- MORAb-202-G000-201: A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a folate receptor alpha (FR?)-targeting antibody-drug conjugate (ADC) in Subjects With Selected Tumor Types
Clinical Trial
MORAb-202-G000-201: A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a folate receptor alpha (FR?)-targeting antibody-drug conjugate (ADC) in Subjects With Selected Tumor Types
There are 2 parts to this study. The first part (Dose Escalation) is to study and identify the highest tolerable safe dose of MORAB-202.Not all patients will get the same dose of the study drug. The second part (Dose Expansion) is to further investigate how the different tumor types being studied respond to the study drug and to gather more information on its safety and effectiveness.
Eligibility Criteria
- Inclusion criteria: Subjects must have TNBC, EC, NSCLC or ovarian cancer, and radiological disease progression on or after the most recent therapy by investigator assessment. Exclusion criteria: Subjects will be excluded from this study if they meet criteria such as: received previous treatment with any folate receptor targeting agents; have platinum refractory ovarian cancer; or have brain or subdural metatases.
RESEARCH. INNOVATION. DISCOVERY.